All In Biotech

Drug Trial Radar · NCT00761215

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

Sep 17, 2008

Primary completion

Feb 24, 2009

Study completion Feb 24, 2009

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.

Conditions

  • Skin Diseases, Infectious
  • Skin Diseases, Bacterial

Interventions

  • TR-701 200 mgDrug

    oral TR-701 200 mg for 5 to 7 days

  • TR-701 300 mgDrug

    oral TR-701 300 mg for 5 to 7 days

  • TR-701 400 mgDrug

    TR-701 400 mg for 5 to 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis SetTime frame: 7 to 14 days after the last dose of study drug
  2. Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis SetTime frame: 7-14 days after last dose of study drug

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Trius Study Site #011

    Dothan, Alabama

  • Trius Study site #001

    Chula Vista, California

  • Trius Study Site #009

    Long Beach, California

  • Trius Study site #002

    Oceanside, California

  • Trius Study site #010

    Pasadena, California

  • Trius Study site 007

    San Francisco, California

  • Trius Study site 003

    San Jose, California

  • Trius Study site 004

    Columbus, Georgia

  • Trius Study site #006

    Ludowici, Georgia

  • Trius Study site #005

    Savannah, Georgia

  • Trius Study site #012

    Springfield, Illinois

  • Trius study sie #008

    Detroit, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.